CoChat
Sign Up
Cited by 84Treatment of Major DepressionPsychological Treatments and DisordersTryptophan and brain disorders

A Review of Therapeutic Uses of Mirtazapine in Psychiatric and Medical Conditions

Open access
Alam, Abdulkader, Voronovich, Zoya, Carley, Joseph A.·2013·The Primary Care Companion For CNS Disorders
DOI 10.4088/pcc.13r01525PMC PMC3907331
Open this paper in CoChat — free account

Abstract

Article AbstractObjective: To review the literature examining the use of mirtazapine with an emphasis on its therapeutic benefits for psychiatric patients with comorbid medical conditions.Data Sources: MEDLINE, PsycINFO, Global Health, and AGRICOLA were searched using the terms mirtazapine OR Remeron. Limits were English language, human, year 1980-2012, treatment and prevention, and therapy.Study Selection: Two hundred ninety-three articles were identified.Data Extraction: Identified articles were reviewed with a focus on indications and therapeutic benefits in patients with medical comorbidities.Results: Mirtazapine is an effective antidepressant with unique mechanisms of action. It is characterized by a relatively rapid onset of action, high response and remission rates, a favorable side-effect profile, and several unique therapeutic benefits over other antidepressants. Mirtazapine has also shown promise in treating some medical disorders, including neurologic conditions, and ameliorating some of the associated debilitating symptoms of weight loss, insomnia, and postoperative nausea and vomiting.Conclusions: Mirtazapine offers clinicians multiple therapeutic advantages especially when treating patients with comorbid medical illness.Prim Care Companion CNS Disord 2013;15(5):doi:10.4088/PCC.13r01525© Copyright 2013 Physicians Postgraduate Press, Inc.Submitted: April 29, 2013; accepted July 9, 2013.Published online: October 10, 2013.Corresponding author: Abdulkader Alam, MD, 3520 5th Ave, Lower Level, Ste 1, Pittsburgh, PA 15213 (alama@upmc.edu).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4088/pcc.13r01525

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Topiramate has several molecular actions, including blocking voltage-dependent sodium channels, increasing GABA-A receptor activity, antagonizing some glutamate receptor subtypes, and inhibiting carbonic anhydrase.

    “It is known to have several molecular actions, including blocking voltage-dependent sodium channels, increasing gamma-aminobutyric acid A (GABA-A) receptor activity, antagonizing some glutamate receptor subtypes, and inhibiting carbonic anhydrase.112,113”

    From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [113]

    The Pharmacologic Properties section describes mirtazapine’s receptor actions, not topiramate’s. Searches of our full-text copy for topiramate, sodium channels, GABA-A, and carbonic anhydrase found no passage addressing the claimed mechanisms. This source therefore does not verify the claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 101

  1. [1]Delbressine LP, Moonen ME, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Investig. 1998;15(1):45–55. doi: 10.2165/00044011-199815010-00006. [DOI] [PubMed] [Google Scholar] · DOI
  2. [2]de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995;10(suppl 4):19–23. doi: 10.1097/00004850-199512004-00004. [DOI] [PubMed] [Google Scholar] · DOI
  3. [3]Montgomery S, Schutte A, Reimitz P. Mirtazapine and onset of action of antidepressant activity. Int J Neuropsychopharmacol. 2000;3:249. [Google Scholar]
  4. [4]Behnke K, Søgaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol. 2003;23(4):358–364. doi: 10.1097/01.jcp.0000085408.08426.05. [DOI] [PubMed] [Google Scholar] · DOI
  5. [5]de Boer T, Ruigt GS. The selective [alpha]2-adrenoceptor antagonist mirtazapine (org 3770) enhances noradrenergic and 5-HT1A-mediated serotonergic neurotransmission. CNS Drugs. 1995;4(suppl 1):29–38. [Google Scholar]
  6. [6]De Montigny C, Haddjeri N, Mongeau R, et al. The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems. CNS Drugs. 1995;4(suppl 1):13–17. [Google Scholar]
  7. [7]Bengtsson HJ, Kele J, Johansson J, et al. Interaction of the antidepressant mirtazapine with alpha2-adrenoceptors modulating the release of 5-HT in different rat brain regions in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2000;362(4–5):406–412. doi: 10.1007/s002100000294. [DOI] [PubMed] [Google Scholar] · DOI
  8. [8]Barkin RL, Schwer WA, Barkin SJ. Recognition and management of depression in primary care: a focus on the elderly: a pharmacotherapeutic overview of the selection process among the traditional and new antidepressants. Am J Ther. 2000;7(3):205–226. doi: 10.1097/00045391-200007030-00008. [DOI] [PubMed] [Google Scholar] · DOI
  9. [9]de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57(suppl 4):19–25. [PubMed] [Google Scholar]
  10. [10]Benkert O, Szegedi A, Philipp M, et al. Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder. J Clin Psychopharmacol. 2006;26(1):75–78. doi: 10.1097/01.jcp.0000194622.99986.d6. [DOI] [PubMed] [Google Scholar] · DOI
  11. [11]Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000;38(6):461–474. doi: 10.2165/00003088-200038060-00001. [DOI] [PubMed] [Google Scholar] · DOI
  12. [12]Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry. 1995;56(11):519–525. [PubMed] [Google Scholar]
  13. [13]Zivkov M, De Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. Human Psychopharmacology: Clinical and Experimental. 1995;10(3):173–180. [Google Scholar]
  14. [14]Mullin J, Lodge A, Bennie E, et al. A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression. J Psychopharmacol. 1996;10(3):235–240. doi: 10.1177/026988119601000310. [DOI] [PubMed] [Google Scholar] · DOI
  15. [15]Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Human Psychopharmacology: Clinical and Experimental. 1995;10(S2):S125–S133. [Google Scholar]
  16. [16]van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol. 1995;10(1):3–9. [PubMed] [Google Scholar]
  17. [17]Stahl S, Zivkov M, Reimitz PE, et al. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr Scand suppl. 1997;391(s391):22–30. doi: 10.1111/j.1600-0447.1997.tb05955.x. [DOI] [PubMed] [Google Scholar] · DOI
  18. [18]Wheatley DP, van Moffaert M, Timmerman L, et al. Mirtazapine-Fluoxetine Study Group. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry. 1998;59(6):306–312. [PubMed] [Google Scholar]
  19. [19]Leinonen E, Skarstein J, Behnke K, et al. Nordic Antidepressant Study Group. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol. 1999;14(6):329–337. doi: 10.1097/00004850-199911000-00002. [DOI] [PubMed] [Google Scholar] · DOI
  20. [20]Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry. 2000;61(9):656–663. doi: 10.4088/jcp.v61n0911. [DOI] [PubMed] [Google Scholar] · DOI
  21. [21]Rodriguez AG, Ferrer CG, Odriozola VN. Efficacy and tolerability of mirtazapine versus paroxetine in the treatment of major depressive disorder. Clin Med Insights Therapeutics. 2012;4:57–63. [Google Scholar]
  22. [22]Kim JE, Yoon SJ, Kim J, et al. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. Int J Clin Pract. 2011;65(3):323–329. doi: 10.1111/j.1742-1241.2010.02624.x. [DOI] [PubMed] [Google Scholar] · DOI
  23. [23]Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol. 2010;25(4):189–198. doi: 10.1097/YIC.0b013e328330adb2. [DOI] [PubMed] [Google Scholar] · DOI
  24. [24]Szegedi A, Müller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003;64(4):413–420. doi: 10.4088/jcp.v64n0410. [DOI] [PubMed] [Google Scholar] · DOI
  25. [25]Quitkin FM, Taylor BP, Kremer C. Does mirtazapine have a more rapid onset than SSRIs? J Clin Psychiatry. 2001;62(5):358–361. doi: 10.4088/jcp.v62n0509. [DOI] [PubMed] [Google Scholar] · DOI
  26. [26]Wade A, Crawford GM, Angus M, et al. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol. 2003;18(3):133–141. doi: 10.1097/01.yic.0000068045.82050.00. [DOI] [PubMed] [Google Scholar] · DOI
  27. [27]Guelfi JD, Ansseau M, Timmerman L, et al. Mirtazapine-Venlafaxine Study Group. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol. 2001;21(4):425–431. doi: 10.1097/00004714-200108000-00010. [DOI] [PubMed] [Google Scholar] · DOI
  28. [28]Thase ME, Nierenberg AA, Keller MB, et al. Relapse Prevention Study Group. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry. 2001;62(10):782–788. doi: 10.4088/jcp.v62n1006. [DOI] [PubMed] [Google Scholar] · DOI
  29. [29]Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 1998;13(2):63–73. doi: 10.1097/00004850-199803000-00002. [DOI] [PubMed] [Google Scholar] · DOI
  30. [31]Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163(7):1161–1172. doi: 10.1176/ajp.2006.163.7.1161. [DOI] [PubMed] [Google Scholar] · DOI
  31. [32]Hirschfeld RMA. The use of mirtazapine in difficult-to-treat patient populations. Hum Psychopharmacol. 2002;17(suppl 1):S33–S36. doi: 10.1002/hup.387. [DOI] [PubMed] [Google Scholar] · DOI
  32. [33]Versiani M, Moreno R, Ramakers-van Moorsel CJA, et al. Comparative Efficacy Antidepressants Study Group. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs. 2005;19(2):137–146. doi: 10.2165/00023210-200519020-00004. [DOI] [PubMed] [Google Scholar] · DOI
  33. [34]Morris DW, Budhwar N, Husain M, et al. Depression treatment in patients with general medical conditions: results from the CO-MED trial. Ann Fam Med. 2012;10(1):23–33. doi: 10.1370/afm.1316. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  34. [35]Kang E-H, Lee IS, Chung SK, et al. Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: a randomized, open-labeled trial. Psychiatry Res. 2009;169(2):118–123. doi: 10.1016/j.psychres.2008.06.021. [DOI] [PubMed] [Google Scholar] · DOI
  35. [37]de Jonge P, Honig A, van Melle JP, et al. MIND-IT Investigators. Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. Am J Psychiatry. 2007;164(9):1371–1378. doi: 10.1176/appi.ajp.2007.06091492. [DOI] [PubMed] [Google Scholar] · DOI
  36. [38]Honig A, Kuyper AM, Schene AH, et al. MIND-IT investigators. Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med. 2007;69(7):606–613. doi: 10.1097/PSY.0b013e31814b260d. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  37. [39]Tulner DM, Smith OR, Schins A, et al. Antidepressive effect of mirtazapine in post-myocardial infarction depression is associated with soluble TNF-R1 increase: data from the MIND-IT. Neuropsychobiology. 2011;63(3):169–176. doi: 10.1159/000321624. [DOI] [PubMed] [Google Scholar] · DOI
  38. [40]Niedermaier N, Bohrer E, Schulte K, et al. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry. 2004;65(12):1619–1623. doi: 10.4088/jcp.v65n1206. [DOI] [PubMed] [Google Scholar] · DOI
  39. [41]Kühn K-U, Quednow BB, Thiel M, et al. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy Behav. 2003;4(6):674–679. doi: 10.1016/j.yebeh.2003.08.009. [DOI] [PubMed] [Google Scholar] · DOI
  40. [42]Altintoprak AE, Zorlu N, Coskunol H, et al. Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study. Hum Psychopharmacol. 2008;23(4):313–319. doi: 10.1002/hup.935. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  41. [43]Afshar M, Knapp CM, Sarid-Segal O, et al. The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. Am J Drug Alcohol Abuse. 2012;38(2):181–186. doi: 10.3109/00952990.2011.644002. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  42. [44]Varia I, Venkataraman S, Hellegers C, et al. Effect of mirtazapine orally disintegrating tablets on health-related quality of life in elderly depressed patients with comorbid medical disorders: a pilot study. Psychopharmacol Bull. 2007;40(1):47–56. [PubMed] [Google Scholar]
  43. [45]Roose SP, Nelson JC, Salzman C, et al. Mirtazapine in the Nursing Home Study Group. Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home. Curr Med Res Opin. 2003;19(8):737–746. doi: 10.1185/030079903125002441. [DOI] [PubMed] [Google Scholar] · DOI
  44. [46]Schatzberg AF, Kremer C, Rodrigues HE, et al. Mirtazapine vs Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry. 2002;10(5):541–550. [PubMed] [Google Scholar]
  45. [47]Høyberg OJ, Maragakis B, Mullin J, et al. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand. 1996;93(3):184–190. doi: 10.1111/j.1600-0447.1996.tb10629.x. [DOI] [PubMed] [Google Scholar] · DOI
  46. [49]Cakir S, Kulaksizoglu IB. The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: a 12-week open-label pilot study. Neuropsychiatr Dis Treat. 2008;4(5):963–966. doi: 10.2147/ndt.s3201. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  47. [50]Liappas J, Paparrigopoulos T, Tzavellas E, et al. Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. J Affect Disord. 2003;76(1–3):279–284. doi: 10.1016/s0165-0327(02)00094-0. [DOI] [PubMed] [Google Scholar] · DOI
  48. [51]Liappas J, Paparrigopoulos T, Malitas P, et al. Mirtazapine improves alcohol detoxification. J Psychopharmacol. 2004;18(1):88–93. doi: 10.1177/0269881104040241. [DOI] [PubMed] [Google Scholar] · DOI
  49. [52]Liappas J, Paparrigopoulos T, Tzavellas E, et al. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(1):55–60. doi: 10.1016/j.pnpbp.2004.10.005. [DOI] [PubMed] [Google Scholar] · DOI
  50. [54]Cruickshank CC, Montebello ME, Dyer KR, et al. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal. Drug Alcohol Rev. 2008;27(3):326–333. doi: 10.1080/09595230801935672. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  51. [56]Boshuisen ML, Slaap BR, Vester-Blokland ED, et al. The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol. 2001;16(6):363–368. doi: 10.1097/00004850-200111000-00008. [DOI] [PubMed] [Google Scholar] · DOI
  52. [57]Ribeiro L, Busnello JV, Kauer-Sant’Anna M, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res. 2001;34(10):1303–1307. doi: 10.1590/s0100-879x2001001000010. [DOI] [PubMed] [Google Scholar] · DOI
  53. [58]Sarchiapone M, Amore M, De Risio S, et al. Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol. 2003;18(1):35–38. doi: 10.1097/00004850-200301000-00006. [DOI] [PubMed] [Google Scholar] · DOI
  54. [59]Bahk W-M, Pae CU, Tsoh J, et al. Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study. Hum Psychopharmacol. 2002;17(7):341–344. doi: 10.1002/hup.426. [DOI] [PubMed] [Google Scholar] · DOI
  55. [60]Davidson JRT, Weisler RH, Butterfield MI, et al. Mirtazapine vs placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry. 2003;53(2):188–191. doi: 10.1016/s0006-3223(02)01411-7. [DOI] [PubMed] [Google Scholar] · DOI
  56. [61]Chung MY, Min KH, Jun YJ, et al. Efficacy and tolerability of mirtazapine and sertraline in Korean veterans with posttraumatic stress disorder: a randomized open label trial. Hum Psychopharmacol. 2004;19(7):489–494. doi: 10.1002/hup.615. [DOI] [PubMed] [Google Scholar] · DOI
  57. [62]Seo H-J, Jung Y-E, Bank W-M, et al. A comparison of mirtazapine and paroxetine for the treatment of patients with posttraumatic stress disorder: a randomized open-label trial. Clin Psychopharmacol Neurosci. 2010;8(2):84–89. [Google Scholar]
  58. [63]Alderman CP, Condon JT, Gilbert AL. An open-label study of mirtazapine as treatment for combat-related PTSD. Ann Pharmacother. 2009;43(7):1220–1226. doi: 10.1345/aph.1M009. [DOI] [PubMed] [Google Scholar] · DOI
  59. [64]Koran LM, Gamel NN, Choung HW, et al. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry. 2005;66(4):515–520. [PubMed] [Google Scholar]
  60. [65]Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry. 2004;65(10):1394–1399. doi: 10.4088/jcp.v65n1015. [DOI] [PubMed] [Google Scholar] · DOI
  61. [66]Gambi F, De Berardis D, Campanella D, et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol. 2005;19(5):483–487. doi: 10.1177/0269881105056527. [DOI] [PubMed] [Google Scholar] · DOI
  62. [67]Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2005;25(6):580–583. doi: 10.1097/01.jcp.0000186871.04984.8d. [DOI] [PubMed] [Google Scholar] · DOI
  63. [68]Van Veen JF, Van Vliet IM, Westenberg HGM. Mirtazapine in social anxiety disorder: a pilot study. Int Clin Psychopharmacol. 2002;17(6):315–317. doi: 10.1097/00004850-200211000-00008. [DOI] [PubMed] [Google Scholar] · DOI
  64. [69]Schutters SIJ, Van Megen HJGM, Van Veen JF, et al. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2010;25(5):302–304. doi: 10.1097/yic.0b013e32833a4d71. [DOI] [PubMed] [Google Scholar] · DOI
  65. [70]Schutters SI, van Megen HJ, Van Veen JF, et al. Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo. Hum Psychopharmacol. 2011;26(1):72–76. doi: 10.1002/hup.1165. [DOI] [PubMed] [Google Scholar] · DOI
  66. [71]Major EO, Amemiya K, Tornatore CS, et al. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 1992;5(1):49–73. doi: 10.1128/cmr.5.1.49. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  67. [72]Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306(5700):1380–1383. doi: 10.1126/science.1103492. [DOI] [PubMed] [Google Scholar] · DOI
  68. [73]Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol. 2009;66(2):255–258. doi: 10.1001/archneurol.2008.557. [DOI] [PubMed] [Google Scholar] · DOI
  69. [74]Moenster RP, Jett RA. Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus. Am J Health Syst Pharm. 2012;69(6):496–498. doi: 10.2146/ajhp110392. [DOI] [PubMed] [Google Scholar] · DOI
  70. [75]Lima MA, Auriel E, Wüthrich C, et al. Progressive multifocal leukoencephalopathy as a complication of hepatitis C virus treatment in an HIV-negative patient. Clin Infect Dis. 2005;41(3):417–419. doi: 10.1086/431769. [DOI] [PubMed] [Google Scholar] · DOI
  71. [76]Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438–446. doi: 10.1016/S1474-4422(10)70028-4. [DOI] [PubMed] [Google Scholar] · DOI
  72. [77]Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology. 1999;53(5):1154. doi: 10.1212/wnl.53.5.1154-a. [DOI] [PubMed] [Google Scholar] · DOI
  73. [78]Pahwa R, Lyons KE. Mirtazapine in essential tremor: a double-blind, placebo-controlled pilot study. Mov Disord. 2003;18(5):584–587. doi: 10.1002/mds.10371. [DOI] [PubMed] [Google Scholar] · DOI
  74. [79]Uccellini D, Grampa G, La Spina I, et al. Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study. Neuropsychiatr Dis Treat. 2006;2(1):95–100. [PMC free article] [PubMed] [Google Scholar]
  75. [80]Deuschl G, Raethjen J, Hellriegel H, et al. Treatment of patients with essential tremor. Lancet Neurol. 2011;10(2):148–161. doi: 10.1016/S1474-4422(10)70322-7. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  76. [81]Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology. 2004;62(10):1706–1711. doi: 10.1212/01.wnl.0000127282.90920.8c. [DOI] [PubMed] [Google Scholar] · DOI
  77. [82]Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996;61(3):285–290. doi: 10.1136/jnnp.61.3.285. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI
  78. [83]Bendtsen L, Buchgreitz L, Ashina S, et al. Combination of low-dose mirtazapine and ibuprofen for prophylaxis of chronic tension-type headache. Eur J Neurol. 2007;14(2):187–193. doi: 10.1111/j.1468-1331.2006.01607.x. [DOI] [PubMed] [Google Scholar] · DOI
  79. [84]Arnold P, Vuadens P, Kuntzer T, et al. Mirtazapine decreases the pain feeling in healthy participants. Clin J Pain. 2008;24(2):116–119. doi: 10.1097/AJP.0b013e318159f94a. [DOI] [PubMed] [Google Scholar] · DOI
  80. [85]Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage. 2002;23(5):442–447. doi: 10.1016/s0885-3924(02)00381-0. [DOI] [PubMed] [Google Scholar] · DOI
  81. [86]Samborski W, Lezanska-Szpera M, Rybakowski JK. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry. 2004;37(4):168–170. doi: 10.1055/s-2004-827172. [DOI] [PubMed] [Google Scholar] · DOI
  82. [87]Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs. 1996;5(5):389–402. doi: 10.2165/00023210-199605050-00007. [DOI] [PubMed] [Google Scholar] · DOI
  83. [88]Sussman N, Ginsberg DL. Weight effects of nefazodone, bupropion, mirtazapine, and venlafaxine: a review of available evidence. Prim Psychiatry. 2000;7:33–48. [Google Scholar]
  84. [89]Riechelmann RP, Burman D, Tannock IF, et al. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care. 2010;27(2):106–110. doi: 10.1177/1049909109345685. [DOI] [PubMed] [Google Scholar] · DOI
  85. [90]Boas S, McColley S, Danduran M, et al. The role of mirtazapine as an appetite stimulant in malnourished individuals with CF. Pediatr Pulmonol. 2000;30:325–326. [Google Scholar]
  86. [91]Sykes R, Kittel F, Marcus M, et al. Mirtazapine for appetite stimulation in children with cystic fibrosis. Pediatr Pulmonol. 2006;59:389–390. [Google Scholar]
  87. [92]Chinuck RS, Fortnum H, Baldwin DR. Appetite stimulants in cystic fibrosis: a systematic review. J Hum Nutr Diet. 2007;20(6):526–537. doi: 10.1111/j.1365-277X.2007.00824.x. [DOI] [PubMed] [Google Scholar] · DOI
  88. [93]Himmerich H, Fulda S, Schaaf L, et al. Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care. 2006;29(1):170–171. doi: 10.2337/diacare.29.1.170. [DOI] [PubMed] [Google Scholar] · DOI
  89. [94]Stimmel GL, Sussman N, Wingard P. Mirtazapine safety and tolerability: analysis of the clinical trials database. Prim Psychiatry. 1997;4:82–90. [Google Scholar]
  90. [95]Radhakishun FS, van den Bos J, van der Heijden BC, et al. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J Clin Psychopharmacol. 2000;20(5):531–537. doi: 10.1097/00004714-200010000-00006. [DOI] [PubMed] [Google Scholar] · DOI
  91. [96]Aslan S, Isik E, Cosar B. The effects of mirtazapine on sleep: a placebo controlled, double-blind study in young healthy volunteers. Sleep. 2002;25(6):677–679. [PubMed] [Google Scholar]
  92. [98]Carley DW, Olopade C, Ruigt GS, et al. Efficacy of mirtazapine in obstructive sleep apnea syndrome. Sleep. 2007;30(1):35–41. doi: 10.1093/sleep/30.1.35. [DOI] [PubMed] [Google Scholar] · DOI · Paper page
  93. [99]Marshall NS, Yee BJ, Desai AV, et al. Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea. Sleep. 2008;31(6):824–831. doi: 10.1093/sleep/31.6.824. [DOI] [PMC free article] [PubMed] [Google Scholar] · DOI · Paper page
  94. [100]Saks BR. Mirtazapine: treatment of depression, anxiety, and hyperemesis gravidarum in the pregnant patient: a report of 7 cases. Arch Women Ment Health. 2001;3(4):165–170. [Google Scholar]
  95. [101]Rohde A, Dembinski J, Dorn C. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy. Arch Gynecol Obstet. 2003;268(3):219–221. doi: 10.1007/s00404-003-0502-0. [DOI] [PubMed] [Google Scholar] · DOI
  96. [102]Chen CC, Lin CS, Ko YP, et al. Premedication with mirtazapine reduces preoperative anxiety and postoperative nausea and vomiting. Anesth Analg. 2008;106(1):109–113. doi: 10.1213/01.ane.0000289636.09841.bc. [DOI] [PubMed] [Google Scholar] · DOI
  97. [103]Chang F-L, Ho S-T, Sheen MJ. Efficacy of mirtazapine in preventing intrathecal morphine-induced nausea and vomiting after orthopaedic surgery. Anaesthesia. 2010;65(12):1206–1211. doi: 10.1111/j.1365-2044.2010.06561.x. [DOI] [PubMed] [Google Scholar] · DOI
  98. [104]Saiz-Ruiz J, Montes JM, Ibáñez A, et al. Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study. Hum Psychopharmacol. 2005;20(6):435–440. doi: 10.1002/hup.706. [DOI] [PubMed] [Google Scholar] · DOI
  99. [105]Michelson D, Kociban K, Tamura R, et al. Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. J Psychiatr Res. 2002;36(3):147–152. doi: 10.1016/s0022-3956(01)00060-7. [DOI] [PubMed] [Google Scholar] · DOI
  100. [106]Schutters SI, van Megen HJ, Van Veen JF, et al. Paroxetine augmentation in patients with generalised social anxiety disorder, non-responsive to mirtazapine or placebo. Hum Psychopharmacol. 2011;26(1):72–76. doi: 10.1002/hup.1165. [DOI] [PubMed] [Google Scholar] · DOI
  101. [107]Waldinger MD, Zwinderman AH, Olivier B. Antidepressants and ejaculation: a double-blind, randomized, fixed-dose study with mirtazapine and paroxetine. J Clin Psychopharmacol. 2003;23(5):467–470. doi: 10.1097/01.jcp.0000088904.24613.e4. [DOI] [PubMed] [Google Scholar] · DOI

Cited by

Sorted by citations

Authors
Alam, A., Voronovich, Z., & Carley, J. A.
Affiliations
University of Pittsburgh (US)
Corresponding author
Alam, Abdulkader
ORCID
Venue
The Primary Care Companion For CNS Disorders
Publisher
Physicians Postgraduate Press, Inc
Published
2013-10-10
Volume
15
Issue
5
ISSN
  • 2155-7772 (ISSN-L)
  • 2155-7780
DOI
10.4088/pcc.13r01525
PMC
PMC3907331
OpenAlex
W2038782521
Cited by
84
References
6
Citations by year
2026: 2 · 2025: 8 · 2024: 11 · 2023: 6 · 2022: 7 · 2021: 7 · 2020: 7 · 2019: 11 · 2018: 8 · 2017: 5 · 2016: 7 · 2015: 4 · 2014: 1
FWCI
2.94
Type
journal article
Language
en
Open access
Locations
  • The Primary Care Companion For CNS Disorders (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
mirtazapine, antidepressants, psychiatric comorbidity, comorbidities, weight loss, insomnia, postoperative nausea and vomiting, neurologic conditions, antidepressant mechanism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review